IncellDx
Overview
IncellDx, Inc. is a precision medicine company focused on single-cell diagnostics to advance healthcare by detecting and monitoring viral diseases like HIV, cervical cancer, and COVID-19. Established in 2009 by Dr. Bruce Patterson, the company operated from its headquarters in San Carlos, California. With a funding accumulation of approximately $9.5 million over several investment rounds, IncellDx leads innovations in diagnosing and treating long COVID with its IncellKINE tests distinguishing it from similar conditions.
Recent Developments
- April 2024: IncellDx, in collaboration with PeploBio, launched a laboratory-developed test in the UK and EU to diagnose Long COVID. Utilizing incellKINE Long Hauler Index technology, it provides insights into personalized treatment approaches, marking a critical development in managing long COVID (source).
- July 2024: The company raised $500,000 in a Series B funding round, bringing their total funding to $9.5 million (source).
- February 2024: The FDA approved a randomized clinical trial led by HealthBioAI, using IncellDx's Maraviroc product for Long COVID treatment, highlighting its potential therapeutic impact (source).
- 2023: IncellDx's diagnostic test for long COVID was approved in Europe, providing over 90% accuracy in identifying immunological signals characteristic of long COVID (source).
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2009 |
| Headquarters | San Carlos, California, USA |
| Founders | Dr. Bruce Patterson |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | BioReference Laboratories, among others |
| Industry | Precision Medicine |
| Number of Employees | ~80 |
Early History
Founded in 2009 by virologist Dr. Bruce Patterson, IncellDx started with a mission to revolutionize healthcare by leveraging its proprietary technology that allows for simultaneous cellular analysis and molecular diagnosis. The early focus was on developing assays for significant viral diseases like HIV/AIDS, hepatis, and cancers like cervical and prostate. The company's innovation enabled detailed cellular analysis for diagnostics, laying the foundation for its current emphasis on precision medicine applications.
Company Profile and Achievements
IncellDx has pioneered advancements in precision medicine through its comprehensive approach to simultaneous genomics, proteomics, and cell cycle analysis. Milestones include:
- 2009: IncellDx was founded, beginning its journey with revolutionary single-cell diagnostics.
- 2011: Received ISO certifications reinforcing its quality management systems for medical device manufacturing.
- 2021-2024: Launched innovative diagnostics for long COVID, earning CE-IVD marking in Europe for its IncellKINE test.
- 2023: Its novel diagnostics for long COVID received European regulatory approvals, marking a significant achievement in addressing post-COVID conditions (source).
Current Operations and Market Position
Currently, IncellDx operates at the forefront of precision medicine, notably in the diagnostics of complex viral conditions and cancers. The company’s unique diagnostic platform, which analyses single cells for proteomic and genomic markers, positions it strongly within the healthcare and biotechnology sectors. With its focus on conditions like long COVID, it aims to fill gaps in personalized medicine, treating complex medical conditions with enhanced diagnostic precision.
Conclusion
IncellDx stands as a vital player in the precision medicine arena, largely for its role in revolutionizing diagnostic practices for infectious diseases and cancers. With its cutting-edge technologies like the IncellKINE Long COVID diagnostics, the company underlines potential advancements and significant impacts in personalized healthcare solutions. Looking forward, IncellDx is set to continue expanding its influence globally, particularly in areas that demand high precision medical interventions.